Hepavir 100mg

Tablet

Pack Size : 4 Tablet x 1 Strip

Generics : Lamivudine

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 100.68

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Lamivir - 100mg Incepta Pharmaceuticals Ltd.

Tk 25.00

More Information About - Hepavir 100mg

Description

Generic Name

Lamivudine

Precaution

Discontinue use if there is rapid increase in aminotransferase levels, progressive hepatomegaly, or metabolic or lactic acidosis of unknown origin. Discontinue use if clinical signs, symptoms or lab abnormalities suggestive of pancreatitis develop. Hepatomegaly or other risk factors for hepatic impairment. Monitor hepatic function in chronic hepatitis B patients. Exclude HIV infection prior to hepatitis B therapy. Renal impairment. Pregnancy.

Indication

HIV infection, Chronic hepatitis B

Contra Indication

Hypersensitivity. Lactation.

Dose

N/A

Side Effect

>10% Cough,Diarrhea,Fatigue & malaise,Fever (peds),Headache,Musculoskeletal pain,Nausea,Nervous system neuropathy,Pancreatitis,Peripheral neuropathy,Nasal S/S,Vomiting 1-10% Abdominal cramps, abdominal pain,Anorexia &/or decr appetite,Arthralgia,Chills,Depression,Dizziness,Dyspepsia,Insomnia,Myalgia,Rash,Thrombocytopenia,Creatine phosphokinase increased Frequency Not Defined Body fat redistribution,Elevated amylase,Neutropenia,Hepatitis B exacerbation Potentially Fatal: Lactic acidosis associated with severe hepatomegaly and hepatic steatosis.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Lamivudine, a nucleoside analogue, is phosphorylated in the body to the active triphosphate form. In the active form, it inhibits hepatitis B virus polymerase and HIV reverse transcriptase enzymes.

Interaction

Renal excretion may be inhibited by high doses of trimethoprim (co-trimoxazole). May antagonise the antiviral action of zalcitabine.

Pregnancy Category Note

Pregnancy Available data from the APR show no difference in the overall risk of birth defects for lamivudine or zidovudine compared with background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population; APR uses the MACDP as the U.S. reference population for birth defects in the general population; MACDP evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks gestation; rate of miscarriage is not reported in the APR Lactation The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed infants to avoid risking postnatal transmission of HIV-1 infection; lamivudine is present in human milk; there is no information on effects of lamivudine or zidovudine on breastfed infant or effects of drugs on milk production; because of potential for (1) HIV-1 transmission (in HIV-negative infants), (2)developing viral resistance (in HIV-positive infants), and (3) serious adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they are receiving therapy

Adult Dose

Oral HIV infection Adult: 150 mg bid or 300 mg once daily, in combination with other antiretrovirals. Chronic hepatitis B Adult: 100 mg once daily. For patients with concomitant HIV infection: 300 mg once daily or in 2 divided doses.

Child Dose

Oral HIV infection Child: 3 mth-12 yr: 4 mg/kg bid. Max: 300 mg/day. Chronic hepatitis B Child: >2 yr: 3 mg/kg once daily. Max: 100 mg/day.

Renal Dose

Oral HIV infection Renal impairment: Dialysis patients: Not recommended. CrCl (ml/min) 30-49 1st dose 150 mg, then 150 mg once daily. 15-29 1st dose 150 mg, then 100 mg once daily. 5-14 1st dose 150 mg, then 50 mg once daily. <5 1st dose 50 mg, then 25 mg once daily. Chronic hepatitis B Renal impairment: Haemodialysis patients: Dose adjustment in accordance with CrCl. Peritoneal dialysis patients: Not recommended. CrCl (ml/min) 30-49 1st dose 100 mg, then 50 mg once daily. 15-29 1st dose 100 mg, then 25 mg once daily. 5-14 1st dose 35 mg, then 15 mg once daily. <5 1st dose 35 mg, then 10 mg once daily.

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.